Biosimilars production in Africa opportunities & amp; challenges

Regul Toxicol Pharmacol. 2024 Apr 16;149:105626. doi: 10.1016/j.yrtph.2024.105626. Online ahead of print.ABSTRACTThe healthcare systems of African nations heavily rely on importing and repackaging biological medicine. More than 70% of the pharmaceutical products consumed in Africa are imported. The localization of biosimilar production can have a positive impact on the availability and cost of these products by reducing the expenses for African governments and making essential healthcare products more accessible to the population. However, it is evident that the developing countries, particularly African nations, face various obstacles and difficulties in localizing biosimilar production. These challenges encompass development, manufacturing, evaluation, and registration processes. In this review, we will highlight the significant hurdles and achievements encountered during the localization process of biosimilars.PMID:38636774 | DOI:10.1016/j.yrtph.2024.105626
Source: Regulatory Toxicology and Pharmacology : RTP - Category: Toxicology Authors: Source Type: research